CRESCENT BIOPHARMA, INC.

# Crescent Biopharma, Inc. (CBIO)

This Waltham, Massachusetts-based biotechnology company focuses on the research and development of cancer immunotherapy candidates. The company's pipeline centers on bispecific antibodies designed to address solid tumors through novel mechanisms of action. CR-001, its lead program, is a proprietary anti-PD-1/anti-VEGF bispecific antibody that targets both immune checkpoint and angiogenesis pathways. The company also has earlier-stage candidates designated CR-002 and CR-003 in development.

Crescent Biopharma operates through a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a Chinese pharmaceutical manufacturer, for development and commercialization of oncology therapeutics and novel drug combinations. This partnership arrangement represents a significant portion of the company's business infrastructure and development strategy. The company was incorporated in the Cayman Islands and is listed on Nasdaq, with its principal operations based in the United States.

The company remains in the preclinical and early clinical development stages, with limited disclosed revenue information. As a clinical-stage biotechnology company, Crescent Biopharma's operations are primarily centered on drug development, regulatory pathway advancement, and partnership management rather than commercial product sales.